A b s t r a c t
The inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is present in approximately 1% of patients with myelodysplastic syndrome (MDS) and in a subset of patients with acute myeloid leukemia (AML) and the blast phase of myeloproliferative neoplasms. [1] [2] [3] [4] Patients with inv(3)/t(3;3)-associated myeloid neoplasms often have anemia. The platelet count may be normal or increased. The bone marrow typically shows increased numbers of small hypolobated megakaryocytes and multilineage dysplasia. 1, 2 In the current World Health Organization (WHO) classification of myeloid neoplasms, AML associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is recognized as a distinct entity, included with the group of AMLs with recurrent genetic abnormalities. 3 These AML cases can arise de novo or in patients with MDS. Conventional cytogenetic analysis often shows additional cytogenetic aberrations such as loss of chromosome 7, 5q deletion, or a complex karyotype. 2, 4 Patients with AML associated with inv(3)(q21q26.2)/t(3;3) (q21;q26.2) frequently have disease refractory to conventional chemotherapy regimens and a short overall survival (OS). 1, 5 In the WHO classification, for some types of AML with recurrent cytogenetic abnormalities, the detection of the cytogenetic or molecular abnormality defines the presence of disease, irrespective of blast count. For example, patients with acute promyelocytic leukemia associated with t(15;17) (q22;q21)/PML-RARA have the disease even when the blast/promyelocyte count is less than the 20% threshold. The WHO classification is much more circumspect for patients with inv(3)(q21q26.2/t(3;3)(q21;q26.2), stating that patients with fewer than 20% blasts "must be monitored
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closely for development of more definite evidence of AML." Therefore, such cases are classified as MDS. Clearly, a greater understanding of the natural history of patients with MDS associated with inv(3)/t(3;3) is needed. In this study, we analyzed cases of MDS associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) to better appreciate their clinical and pathologic features and to assess their natural history.
Materials and Methods
Cases of MDS associated with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) detected by conventional cytogenetic analysis were obtained from the files of the Department of Hematopathology, M.D. Anderson Cancer Center, Houston, TX, between January 1996 and June 2008. The medical records of each case were reviewed. This study was performed with approval from the institutional review board of our institution.
Air-dried bone marrow aspirate smears and biopsy touch imprints were stained with Wright-Giemsa. Bone marrow biopsy and aspirate clot specimens were fixed in formalin, and cut slides were stained with H&E.
Bone marrow aspirate specimens were prepared for conventional cytogenetic analysis using methods described previously. 6 Metaphases were banded by the standard GTG method. Chromosome abnormalities were identified according to guidelines for cancer cytogenetics. 6 A subset of cases was assessed for RAS and/or FLT3/ITD or FLT3/D835 mutations using methods described before. 7, 8 Kaplan-Meier estimates were used to assess OS calculated from the date of diagnosis of MDS. Survival curves were compared by using a double-sided log-rank test (Mantel-Cox). The χ 2 and Student t tests were used to analyze the differences between 2 groups of patients. Results were significant at a P level of less than .05. GraphPad Prism 5 (GraphPad Software, La Jolla, CA) was used for statistical analysis.
Results

Clinical and Pathologic Features
There were 14 cases of de novo disease and 6 were therapy-related MDS (t-MDS). The clinical and pathologic features patients are summarized in ❚Table 1❚ and ❚Table 2❚.
The patients were 10 men and 10 women with a median age of 64 years (range, 15- 500-3,500/μL [0.5-3.5 × 10 9 /L]; median, 2,500/μL [2.5 × 10 9 /L]; reference range, 4,000-11,000/μL [4.0-11.0 × 10 9 /L]). The bone marrow biopsy specimens in the de novo cases showed normal or hypercellular bone marrow associated with megakaryocytic hyperplasia ❚Image 1A❚. These megakaryocytes were dysplastic and often had small monolobated or hypolobated nuclei (Image 1A) ❚Image 1B❚. The bone marrow was hypocellular in 5 cases of t-MDS, and in 1 such case, the initial differential diagnoses included aplastic anemia. Bone marrow aspirate smears also showed dysplasia involving the erythroid and myeloid lineages. The bone marrow blast count ranged from 0% to 10% ❚Image 1C❚ and ❚Image 1D❚. An iron stain was performed in 10 cases, and 6 cases showed ring sideroblasts in a range of 2% to 10%.
The morphologic classification of de novo cases using the WHO classification was as follows: 8 refractory cytopenia with multilineage dysplasia, 3 refractory anemia with excess blasts (RAEB), and 3 chronic myelomonocytic leukemia (CMML). The bone marrow blast counts in 3 cases of RAEB were 8%, 10%, and 10%, respectively. The CMML cases were further classified as 1 CMML-1 with 2% blasts and 2 CMML-2 with 10% blasts each.
Eight de novo cases were managed by supportive care such as transfusion and/or growth factors. Of the 8 patients, 2 received azacitidine, 1 received decitabine, and 1 received azacitidine and decitabine. One patient with RAEB received gemtuzumab ozogamicin, and one patient received cord blood stem cell transplantation after conditioning with total body irradiation and cyclophosphamide.
In the group of 6 t-MDS cases, 5 patients were originally diagnosed with lymphoma: 3 nodular sclerosis Hodgkin lymphoma, 1 follicular lymphoma, and 1 diffuse large B-cell lymphoma. One patient had ductal carcinoma of the breast. Five patients had relapses or metastases and were treated with multiple cycles of chemotherapy that spanned several years. The intervals from the diagnosis of primary tumor and the diagnosis of t-MDS ranged from 22 to 156 months. The t-MDS cases were treated more actively with various therapeutic agents from the time of initial diagnosis instead of supportive care. Two patients had allogeneic stem cell transplantation and 1, autologous transplantation.
Conventional Cytogenetic and Molecular Findings
The inv(3)(q21q26.2) was identified in 16 cases and t(3;3)(q21;q26.2) in 4. In 4 cases, there was an isolated inv(3) or t(3;3), whereas 16 cases had additional cytogenetic aberrations. The -7/7q was the most common abnormality, in 7 de novo cases and all 6 t-MDS cases. In 6 cases, there was the -5/5q, detected concurrently with -7/7q in 5 cases. Five cases had a complex karyotype. The frequency of -7/7q was more common in t-MDS than in de novo cases (7/14 vs 6/6; P = .05). The frequency of -5/5q (5/14 vs 1/6; P = .61) or a complex karyotype (4/14 vs 1/6 t-MDS; P = 1.0) was similar between the 2 subgroups.
The -7/7q and inv(3)/t(3;3) were detected simultaneously in 10 cases and sequentially in 3 cases. In 1 de novo case, the initial cytogenetic analysis revealed only t (3;3) . A subsequent analysis performed 3 months later detected 2 abnormal clones: one with isolated t(3;3) and the other with t(3;3) and -7, indicating that -7 was a secondary change. By contrast, in 2 other cases, 1 t-MDS and 1 de novo, detection of -7 bone marrow transplantation. Despite aggressive treatment, 13 patients died of disease with a median survival of 13 months (range, 4-31 months). Follow-up of 6 patients with t-MDS revealed that 4 patients progressed to t-AML during a period of 8 to 11 months. All 6 patients died, with a median survival of 17.5 months (range, 11-33 months).
As shown in ❚Figure 1A❚, the OS of patients with de novo disease was comparable to that of patients with t-MDS (P = .09). There was also no significant difference in the frequency of AML between the 2 subgroups (P = 1). The presence of -7/7q did not confer a worse prognosis in the de novo group (P = .49) ❚Figure 1B❚, nor did a complex karyotype (P = .71) ❚Figure 1C❚. We could not perform a statistical analysis in the t-MDS cases owing to a limited number of cases.
Discussion
The inv(3)/t(3;3) is a rare recurrent cytogenetic abnormality in a subset of cases of AML, MDS, and the blast phase of chronic myeloid leukemia. The 3q21q26.2 preceded that of inv(3) by 1 and 6 months, respectively. In the t-MDS case, the inv(3) was identified within 1 of 2 preexisting abnormal clones that harbored -7, indicating that inv(3) evolved as a secondary event. It is interesting that emergence of inv(3) also coincided with morphologic changes: a rising platelet count from 198 to 599 × 10 3 /μL (198 to 599 × 10 9 /L) in the de novo case and increased bone marrow blasts, from less than 5% to 8%, in both cases.
A RAS mutation was detected in 1 of 15 cases tested (CMML-2), and an FLT3 mutation was not detected in any of 12 cases tested.
Survival Comparison Between De Novo MDS and t-MDS With inv(3)/t(3;3)
Of the 14 patients with de novo diseases, AML developed in 9 patients within 2 to 10 months (median, 6 months). In 3 patients, disease progressed from refractory cytopenia with multilineage dysplasia to RAEB within 2 to 8 months. In 1 patient with CMML-1, CMML-2 developed within 1 month. Patients with AML were treated with combination chemotherapy with or without novel or investigative agents. Two patients also received allogeneic 17, 18 It can occur de novo or arise from a preceding MDS. In the present study, we demonstrated that MDS cases with inv(3)/t(3;3) are associated with a dismal clinical outcome, characterized by chemoresistance, a high risk of leukemic transformation, and a short survival. Furthermore, de novo MDS and t-MDS cases share common features in their clinical and pathologic manifestations. A recent study demonstrated that AML with inv(3)/t(3;3) is associated with an adverse outcome with a median survival of 9.6 months, 19 which is comparable to median survival rates seen in this study. In addition, in nearly 65% of cases in the present study, the disease progressed to acute leukemia. These findings suggest that MDS and AML associated with inv(3)/t(3;3) may represent a continuum of the same entity. The slightly longer survival in the t-MDS group may have been a result of more active intervention once the diagnosis of t-MDS was established compared with supportive care received by patients with low-grade de novo MDS.
In the current WHO classification, AML in patients with t(8;21), inv(16), or t(15;17) is classified as such even when a blast or promyelocyte count is less than 20%. In our opinion, the results from this study suggest that this rule could be applied to patients with myeloid neoplasms associated with inv(3)/t(3;3). This approach allows for more intensive intervention such as stem cell transplantation, which may potentially yield a better outcome in appropriate candidates.
Similar to what was found in AML associated with the inv(3)/t(3;3) abnormality, 4,20 patients with MDS also frequently have additional cytogenetic aberrations. The -7/7q and -5/5q were detected in about 65% and 30% of cases, respectively, in this study. The relationship between 3q21q26.2 and -7/7q remains to be elucidated. In our series, chromosome 7 aberrations occurred before, simultaneously, or after the onset of 3q21q26.2 rearrangement. A recent study by Stein et al 21 sheds light on the link between EVI1 activation and the development of monosomy. In this study, insertional activation of MDS1-EVI1 and, subsequently, the development of monosomy 7 and MDS were identified in 2 patients with X-linked chronic granulomatous disease treated with gene therapy. Furthermore, increased genomic instability is identified in MDS1-EVI1-expressing cells, and overexpression of EVI1 in human diploid fibroblasts leads to increased frequency of centrosomal aberration.
In summary, to our knowledge this is the first study to characterize and compare de novo MDS and t-MDS with inv(3)/t(3;3). The patients have a dismal clinical outcome characterized by short overall and median survival rates and high risk of disease progression to AML. Additional cytogenetic abnormalities, including -7/7q, -5/5q, or complex cytogenetic aberrations, are common findings associated with MDS with inv(3)/t(3;3).
